WHO trial to assess other antibody, antiviral drugs after remdesivir doubt
[GENEVA] The World Health Organization (WHO) said on Friday it would assess monoclonal antibodies and other antiviral drugs in its trial of potential Covid-19 treatments, after the trial found Gilead Science's remdesivir had no impact on survival rates.
WHO director-general Tedros Adhanom Ghebreyesus said its Solidarity Trial would continue after it was launched in March in 500 hospitals in 30 countries to assess the efficacy of remdesivir and several other drugs in patients with Covid-19.
"The Solidarity Trial is still recruiting about 2,000 patients every month and will assess other treatments, including monoclonal antibodies and new antivirals," Tedros told a news conference.
The Solidarity Trial was at the centre of a dispute on Friday between the WHO and Gilead, the US company that developed remdesivir, which said the WHO trial's findings appeared inconsistent with evidence from other studies.
REUTERS
BT is now on Telegram!
For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes
International
Overcrowded Venice introduces first payment charge for tourists
South Korea readies new system to detect illegal short-selling
US births retreat after pandemic-era growth
Markets are embracing India’s Modi for what he won’t do
Blinken to meet businesses in Shanghai as he kicks off a tough China trip
Indonesia’s central bank surprises with ‘pre-emptive’ rate hike to cushion falling rupiah